Kelly Fitzgerald, MD
Assistant Professor
Medicine
School of Medicine

Education & Training

Show all (2) Hide

• Medical Oncology fellowship Memorial Sloan Kettering Cancer Center 06/2023
• Internal Medicine residency UCSF 06/2017

Publications (10)

Top publication keywords:
Antineoplastic AgentsKidney NeoplasmsVascular Endothelial Growth Factor AImmunotherapySkin NeoplasmsCD47 AntigenEpitopesImmunotherapy, AdoptiveCarcinoma, Renal CellNeoplasm Recurrence, LocalIpilimumabCarcinoma, Squamous CellAntigens, CD19Receptors, Antigen, T-CellLymphoma, B-Cell

• Genomic ancestry in kidney cancer: Correlations with clinical and molecular features.
  Cancer 2023 Kotecha RR, Knezevic A, Arora K, Bandlamudi C, Kuo F, Carlo MI, Fitzgerald KN, Feldman DR, Shah NJ, Reznik E, Hakimi AA, Carrot-Zhang J, Mandelker D, Berger M, Lee CH, Motzer RJ, Voss MH
• Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade.
  Nature reviews. Urology 2022 Fitzgerald KN, Motzer RJ, Lee CH
• Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.
  European urology 2022 Fitzgerald KN, Duzgol C, Knezevic A, Shapnik N, Kotecha R, Aggen DH, Carlo MI, Shah NJ, Voss MH, Feldman DR, Motzer RJ, Lee CH
• Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options.
  Journal of the National Comprehensive Cancer Network : JNCCN 2022 Fitzgerald KN, Lee CH
• Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas.
  European urology focus 2022 Yoo A, Tang C, Zucker M, Fitzgerald K, DiNatale RG, Rappold PM, Weiss K, Freeman B, Lee CH, Schultz N, Motzer R, Russo P, Coleman J, Reuter VE, Chen YB, Carlo MI, Gill AJ, Kotecha RR, Ari Hakimi A, …

Show all (5 more) Hide

• CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas.
  Leukemia & lymphoma 2021 Fitzgerald KN, Quesada AE, von Keudell G, Raj S, Lewis NE, Dogan A, Salles G, Palomba ML
• J Clin Oncol
  Response to PD-1 inhibition in early- and late-relapsing cutaneous melanoma. 2019 Fitzgerald, K and Daud, A.
• Systemic therapy for advanced cutaneous squamous cell carcinoma.
  Seminars in cutaneous medicine and surgery 2019 Fitzgerald K, Tsai KK
• MYC regulates the antitumor immune response through CD47 and PD-L1.
  Science (New York, N.Y.) 2016 Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, Felsher DW
• A comparison of non-integrating reprogramming methods.
  Nature biotechnology 2014 Schlaeger TM, Daheron L, Brickler TR, Entwisle S, Chan K, Cianci A, DeVine A, Ettenger A, Fitzgerald K, Godfrey M, Gupta D, McPherson J, Malwadkar P, Gupta M, Bell B, Doi A, Jung N, Li X, Lynes MS, …